Prednisolone combined with adjunctive immunosuppression is not superior to prednisolone alone in terms of efficacy and safety in giant cell arteritis: Meta-analysis

Clinical Rheumatology

Volumn 33, Issue 2, 2014, Pages 227-236

  Yates, M ^a,b   Loke, Y K ^c   Watts, R A ^c   MacGregor, A J ^a,b,c  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Giant cell arteritis; Glucocorticoids; Immunosuppression; Meta analysis; Treatment; Vasculitis

Indexed keywords

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; DAPSONE; FEMALE; GIANT CELL ARTERITIS; HUMANS; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; PREDNISOLONE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME; VASCULITIS;

EID: 84893981746     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-013-2384-2     Document Type: Article

References (38)

1. Smeeth L (2006) Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the UK, 1990-2001. Ann Rheum Dis 65(8):1093-1098. doi: 10.1136/ard.2005.046912, published Online First: Epub Date
2. Birkhead NC, Wagener HP, Shick RM (1957) Treatment of temporal arteritis with adrenal corticosteroids; results in fifty-five cases in which lesion was proved at biopsy. JAMA 163(10):821-827
3. Shick RM, Baggenstoss AH, Fuller BF et al (1950) Effects of cortisone and ACTH on periarteritis nodosa and cranial arteritis. Proc Staff Meet Mayo Clin 25(17):492-494
4. Loddenkemper T, Sharma P, Katzan I et al (2007) Risk factors for early visual deterioration in temporal arteritis. J Neurol Neurosurg Psychiatry 78(11):1255-1259
5. Gonzalez-Gay MA, Blanco R, Rodriguez-Valverde V et al (1998) Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum 41(8):1497-1504. doi: 10.1002/1529-0131(199808)41:8<1497::aid-art22>3.0.co;2-z, published Online First: Epub Date
6. Proven A, Gabriel SE, Orces C et al (2003) Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 49(5):703-708
7. Mukhtyar C, Guillevin L, Cid MC et al (2009) EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 68(3):318-323. doi: 10.1136/ard.2008.088351, published Online First: Epub Date
8. Dasgupta B, Borg FA, Hassan N et al (2010) BSR and BHPR Guidelines for the management of giant cell arteritis. Rheumatology. doi: 10.1093/rheumatology/ keq039b, published Online First: Epub Date
9. Matteson EL, Gold KN, Bloch DA et al (1996) Long-term survival of patients with giant cell arteritis in the American College of Rheumatology giant cell arteritis classification criteria cohort. Am J Med 100(2):193-196
10. Gran JT, Myklebust G, Wilsgaard T et al (2001) Survival in polymyalgia rheumatica and temporal arteritis: a study of 398 cases and matched population controls. Rheumatology 40(11):1238-1242
11. Narvaez J, Vives LL, Estrada P, et al (2010) Severe and opportunistic infections during giant cell arteritis course: A case-control study. Arthritis Rheum;Conference: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP 10 Philadelphia, PA United States. Conference Start: 20091016 Conference End: 20091021. Conference Publication: (var.pagings). 62:1310
12. Mahr AD, Jover JA, Spiera RF et al (2007) Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 56(8):2789-2797. doi: 10.1002/art.22754, published Online First: Epub Date
13. Public, Health, Resource, et al (2006) Critical appraisal skills programme (CASP): Making Sense of Evidence 10 Questions to Help You Make Sense of Randomised Controlled Trials
14. Furukawa TA, Barbui C, Cipriani A et al (2006) Imputing missing standard deviations in meta-analyses can provide accurate results. J Clin Epidemiol 59(1):7-10. doi: 10.1016/j.jclinepi.2005.06.006, published Online First: Epub Date
15. Bengtsson BA, Malmvall BE (1981) An alternate-day corticosteroid regimen in maintenance therapy of giant cell arteritis. Acta Med Scand 209(5):347-50
16. De Silva M, Hazleman BL (1986) Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Annals of the rheumatic diseases 45(2):136-8
17. Liozon F, Barrier J, Vidal E, et al (1990) Treatment of giant cell arteritis with dapsone: Effectiveness and side-effects. [French]. Revue de Medecine Interne 11(5):364-70
18. Mariette X, Baron G, Hachulla E, et al (2011) Results of a randomized controlled study of adalimumab for steroid sparing in patients with giant-cell arteritis. Arthritis and Rheumatism 1)
19. Martinez-Taboada VM, Rodriguez-Valverde V, Carreno L, et al (2008) A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Annals of the Rheumatic Diseases 67(5):625-30
20. Schaufelberger C, Andersson R, Nordborg E (1998) No additive effect of cyclosporin a compared with glucocorticoid treatment alone in giant cell arteritis: Results of an open, controlled, randomized study [4]. British Journal of Rheumatology 37(4):464-65
21. Hunder GG, Sheps SG, Allen GL et al (1975) Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study. Annals Intern Med 82(5):613-618
22. Chevalet P, Barrier JH, Pottier P et al (2000) A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one-year follow up study of 164 patients. J Rheumatol 27(6):1484-1491
23. Mazlumzadeh M, Hunder GG, Easley KA et al (2006) Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum 54(10):3310-3318
24. Spiera RF, Mitnick HJ, Kupersmith M et al (2001) A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol 19(5):495-501
25. Jover JA, Hernandez-Garcia C, Morado IC et al (2001) Combined treatment of giant-cell arteritis with methotrexate and prednisone: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 134(2):106-114
26. Hoffman GS, Cid MC, Hellmann DB et al (2002) A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 46(5):1309-1318
27. Liozon F, Vidal E, Barrier JH (1993) Dapsone in giant cell arteritis treatment. Eur J Intern Med 4(3):207-214
28. Hoffman GS, Cid MC, Rendt-Zagar KE et al (2007) Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis a randomized trial. Ann Internal Med 146(9):621-630
29. Seror R, Baron G, Hachulla E et al (2013) Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. Ann Rheum Dis. doi: 10.1136/annrheumdis-2013-203586, published Online First: Epub Date
30. Sailler L, Lapeyre-Mestre M, Geffray L, et al (2009) Adding hydroxychloroquine to prednisone does not improve the outcome in giant cell arteritis: A double blind randomized controlled trial. Arthritis Rheum;Conference: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP 09 Atlanta, GA United States. Conference Start: 20101106 Conference End: 20101111. Conference Publication: (var.pagings). 60:1972
31. Seitz M, Reichenbach S, Bonel HM et al (2011) Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly 141:w13156. doi: 10.4414/smw.2011.13156, published Online First: Epub Date
32. Christidis D, Jain S, Gupta BD (2011) Successful use of tocilizumab in polymyalgic onset biopsy positive GCA with large vessel involvement. BMJ Case Rep. doi: 10.1136/bcr.04.2011.4135, published Online First: Epub Date
33. Salvarani C, Magnani L, Catanoso M et al (2012) Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology 51(1):151-156. doi: 10.1093/rheumatology/ker296, published Online First: Epub Date
34. Terrier B, Geri G, Chaara W et al (2011) IL-21 modulates Th1 and Th17 responses in giant cell arteritis. Arthritis Rheum. doi: 10.1002/art.34327, published Online First: Epub Date
35. Deng J, Younge BR, Olshen RA et al (2010) Th17 and Th1 T-cell responses in giant cell arteritis. Circulation 121(7):906-915. doi: 10.1161/ circulationaha.109.872903, published Online First: Epub Date
36. Samson M, Audia S, Fraszczak J et al (2012) Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. Arthritis Rheum 64(11):3788-3798. doi: 10.1002/art.34647, published Online First: Epub Date
37. Espígol-Frigolé G, Corbera-Bellalta M, Planas-Rigol E et al (2012) Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis. Ann Rheum Dis. doi: 10.1136/annrheumdis-2012-201836, published Online First: Epub Date
38. Direskeneli H, Aydin SZ, Kermani TA et al (2011) Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda. J Rheum 38(7):1471-1479. doi: 10.3899/jrheum.110275, published Online First: Epub Date